Related references
Note: Only part of the references are listed.Interstitial Lung Disease and Lung Cancer Development: A 5-Year Nationwide Population-Based Study
Won-Il Choi et al.
CANCER RESEARCH AND TREATMENT (2018)
Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review
Hanbo Chen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis
Chee Khoon Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia
Daichi Fujimoto et al.
LUNG CANCER (2017)
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
Terufumi Kato et al.
LUNG CANCER (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Concurrence of nivolumab-induced interstitial lung disease and cancer invasion
Osamu Kanai et al.
RESPIROLOGY CASE REPORTS (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2016)
Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival
Nobuhiro Kanaji et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small Cell Lung Cancer
Daichi Fujimoto et al.
PLOS ONE (2016)
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Mizuki Nishino et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer
Takumi Sakurada et al.
ANNALS OF PHARMACOTHERAPY (2015)
Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival
Mizuki Nishino et al.
EUROPEAN JOURNAL OF RADIOLOGY (2015)
Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases
Toshihiko Sato et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2015)
Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer
Nami Ueki et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Masayuki Takeda et al.
LUNG CANCER (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenstrom Macroglobulinemia as a Paradigm
Mizuki Nishino et al.
ONCOLOGIST (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer
Toshihiko Sato et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non-Small-Cell Lung Cancer (NSCLC) An Interim Analysis of 3488 Patients (POLARSTAR)
Kazuhiko Nakagawa et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Risk Factors for Treatment-Related Death Associated with Chemotherapy and Thoracic Radiotherapy for Lung Cancer
Yuko Minami-Shimmyo et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia
Takashi Kinoshita et al.
ONCOLOGY LETTERS (2012)
Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease Incidence and Predicting Factors
Juan P. de Torres et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
M Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis
K Demopoulos et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2002)
Share Paper
